



Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease

This is the peer reviewed version of the following article:

Original:

Cameli, P., Bargagli, E., Bergantini, L., Refini, R.M., Pieroni, M., Sestini, P., et al. (2019). Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease. JOURNAL OF BREATH RESEARCH, 13(2), 1-7 [10.1088/1752-7163/ab0233].

Availability:

This version is available <http://hdl.handle.net/11365/1069001> since 2019-02-27T16:39:27Z

Published:

DOI:10.1088/1752-7163/ab0233

Terms of use:

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

ACCEPTED MANUSCRIPT

Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease

To cite this article before publication: Paolo Cameli *et al* 2019 *J. Breath Res.* in press <https://doi.org/10.1088/1752-7163/ab0233>

Manuscript version: Accepted Manuscript

Accepted Manuscript is “the version of the article accepted for publication including all changes made as a result of the peer review process, and which may also include the addition to the article by IOP Publishing of a header, an article ID, a cover sheet and/or an ‘Accepted Manuscript’ watermark, but excluding any other editing, typesetting or other changes made by IOP Publishing and/or its licensors”

This Accepted Manuscript is © 2018 IOP Publishing Ltd.

During the embargo period (the 12 month period from the publication of the Version of Record of this article), the Accepted Manuscript is fully protected by copyright and cannot be reused or reposted elsewhere.

As the Version of Record of this article is going to be / has been published on a subscription basis, this Accepted Manuscript is available for reuse under a CC BY-NC-ND 3.0 licence after the 12 month embargo period.

After the embargo period, everyone is permitted to use copy and redistribute this article for non-commercial purposes only, provided that they adhere to all the terms of the licence <https://creativecommons.org/licenses/by-nc-nd/3.0>

Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permissions will likely be required. All third party content is fully copyright protected, unless specifically stated otherwise in the figure caption in the Version of Record.

View the [article online](#) for updates and enhancements.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

EVALUATION OF MULTIPLE-FLOWS EXHALED NITRIC OXIDE IN IDIOPATHIC AND NON-IDIOPATHIC INTERSTITIAL LUNG DISEASE

Paolo Cameli¹, Elena Bargagli¹, Laura Bergantini¹, Rosa Metella Refini¹, Maria Pieroni¹, Piersante Sestini¹, Paola Rottoli¹

¹ Department of Medical and Surgical Sciences and Neurosciences, Respiratory Disease and Lung Transplantation Unity, University of Siena, Siena, Italy.

Correspondence: Cameli Paolo, UOC Malattie Respiratorie e Trapianto di Polmone, Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, AOUS, Università di Siena, Viale Bracci 16, 53100 Siena (Italy) Tel. +39 0577 586710 - Fax +39 0577 280744 - E-mail: paolocameli88@gmail.com

The study was conducted at the Department of Medical and Surgical Sciences and Neurosciences, Respiratory Disease and Lung Transplantation Section.

Declarations of interest: none

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

BACKGROUND: Fractional exhaled nitric oxide (FeNO) is a non-invasive and reproducible marker of nitrosative stress and lung inflammation. More recently, FeNO has been proposed as a marker of severity of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis associated ILD.

AIM AND OBJECTIVES: to evaluate the role of FeNO in the diagnostic pathway of ILDs.

METHODS: According to ERS guidelines for exhaled biomarkers in lung diseases, FeNO at multiple flow-rates (50-100-150 and 350 ml/s) and alveolar concentration of NO (CaNO) were collected in 60 healthy controls and 134 patients affected by ILD: 50 with IPF, 19 with fibrotic non-specific interstitial pneumonia (NSIP), 19 with chronic hypersensitivity pneumonia (cHP) and 46 with connective tissue disease related ILD (CTD-ILD). ROC curves were performed to investigate the potential role of eNO parameters in discriminating between idiopathic and non-idiopathic ILDs.

RESULTS: All ILD groups reported higher levels of FeNO 150-350 ml/s and CaNO than controls. Among ILDs, CTD-ILD showed more elevated FeNO 350 ml/s and CaNO levels than other ILD. In particular, CaNO reported the best diagnostic accuracy to discriminate CTD-ILD from idiopathic ILDs.

CONCLUSIONS: Patients affected by ILD reported increased FeNO 150-350 ml/s and CaNO in respect with healthy controls, indicating a potential role of nitrosative stress in lung fibrosis. The significant difference of CaNO levels between idiopathic ILDs and CTD-ILD is interesting and may suggest that NO is also implicated in lung inflammation associated with rheumatological disease. Further evidence is necessary to establish if CaNO is worthy of attention in the differential diagnosis of ILDs.

Keywords: Exhaled nitric oxide; interstitial lung disease; biomarkers; connective tissue disease

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

¹ Abbreviations: nitric oxide (NO), exhaled nitric oxide (eNO), fraction of exhaled NO (FeNO), alveolar concentration of NO (CaNO), maximum conducting airway wall flux (J'awNO), pulmonary function tests (PFT).

INTRODUCTION

Connective tissue diseases associated with Interstitial lung disease (CTD-ILD) is a heterogeneous group of pathologies characterized by the presence of different patterns of interstitial pulmonary involvement associated to a specific connective tissue disorder. The onset of pulmonary disease during the clinical course of CTDs is associated with a significant morbidity and it can impair quality of life and life expectancy. Specific CTDs are often related with particular radiological and histopatological ILD patterns, such as systemic sclerosis (SSC) with non specific interstitial pneumonia (NSIP) [1], Sjogren syndrome (SS) with NSIP or lymphocytic interstitial pneumonia [2] and rheumatoid arthritis (RA) with usual interstitial pneumonia (UIP) [3]. Lung involvement in CTDs is undoubtedly harmful and, in patients affected by SSC, is the main cause of death in endstage disease [4].

The pathogenesis of CTD-ILD is not well understood yet, although it has been reported that immune dysregulation, autoimmune processes, cell senescence, oxidative stress and epithelial dysfunction participate to bronchoalveolar epithelial depauperation, followed by an aberrant proliferation of fibroblasts and epithelial-mesenchymal transition (EMT), that eventually leads to pulmonary fibrosis [5, 6, 7].

Even though the exclusion of CTD in the diagnostic pathway of ILD patients is mandatory, recent researches underlined how idiopathic interstitial pneumonias (IIPs), such as IPF or NSIP, share not only common pathogenetic pathways with CTD-ILD, but also similar outcomes, especially CTD with a pattern of UIP [8].

After the introduction of new specific antifibrotic drugs for IPF patients, new tools to discriminate IIP from CTD-ILD are necessary. Nitric oxide (NO) is a intracellular mediator involved in vasodilation, inflammation and nitrosative-oxidative stress; experimental researches reported an aberrant NO production associated to abnormal lung fibrogenesis [9, 10]. Recent clinical studies have suggested a potential role of fractional exhaled nitric oxide (FeNO) as severity biomarker in patients with ILDs [11].

Tiev et al. suggested that eNO parameters, in particular alveolar concentration of NO (CANO), could be useful in patients with SSC to detect the presence of ILD [12], to predict functional deterioration [13] and

1
2
3 response to cyclophosphamide [14]. They didn't mention a potential role of this parameter to differentiate
4
5 IIP from CTD-ILDs.
6

7
8 The present study aimed to compare FeNO parameters among patients with IIPs, non-idiopathic ILD
9
10 (chronic hypersensitivity pneumonia, cHP) and CTD-ILDs in order to evaluate the different behaviour in
11
12 each specific diffuse lung disease and the potential prognostic role of this indicator.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MATERIALS AND METHODS

1.1 Study population and study design

134 patients with ILDs were recruited at Siena Regional Referral Centre for Sarcoidosis and Interstitial Lung Diseases. ILD population was composed by 50 patients with IPF (30 males, mean age 65 ± 9.1 years), 19 with NSIP (9 males, 66 ± 10 years), 19 with cHP (11 males, 59.2 ± 13 years) and 46 with CTD-ILD (17 males, 62.4 ± 11 years). Among CTD-ILD group, 15 patients had SS, 14 had RA and 17 SSC. Diagnosis was performed according to international guidelines [15,16,17]. No histological sampling (such as transbronchial biopsy, criobiopsy or surgical lung biopsy) has been performed for diagnostic purpose in this population. Medical history was collected in order to investigate professional exposure, smoking status and therapeutic options. All patients were able to perform pulmonary function tests (PFTs), including single-breath diffusing capacity for carbon monoxide. High resolution computed tomography (HRCT) of the chest was performed in all patients for diagnostic purposes to evaluate the specific radiological patterns. All included patients were clinically stable, free of respiratory infections and/or acute exacerbations for at least 8 weeks. Patients with atopy, asthma, cancer or in current therapy with biological agents were excluded in all cases.

60 healthy volunteers (32 males, mean age 61 ± 5 years) were enrolled in the study as control group. History of asthma, recent respiratory infections, inhalant allergies as well as therapy with phosphodiesterase-5 inhibitors were considered as exclusion criteria. They did not receive any pharmacological therapy.

All patients and controls gave their informed consent to the study. The study was conducted according to Declaration of Helsinki principles.

1.2 Study protocol

Exhaled nitric oxide measurements was performed in the morning, in sitting position in a comfortable environment: all participants had been fasting for at least 8 hours before the detection avoiding foods containing nitrates (lettuce, spinach, cabbage, sausages) and high fat foods for at least 12 hours. All participants had a mouthwash with water just before the test. Participants underwent PFTs the same morning after FeNO evaluation (with a distance of almost 2 hours).

1.3 Pulmonary function tests

1
2
3 The following lung function measurements were recorded according to ATS/ERS standards [18, 19], using a
4
5 Jaeger Body Plethysmograph with corrections for temperature and barometric pressure: forced expiratory
6
7 volume in the first second (FEV1), forced vital capacity (FVC), FEV1/FVC, total lung capacity (TLC),
8
9 residual volume (RV), carbon monoxide lung transfer factor (TLCO) and capacity carbon monoxide lung
10
11 transfer factor/alveolar volume (TLCO/VA). TLCO measurement could not be collected in 10 patients
12
13 unable to perform properly single-breath manoeuvres. PFTs were performed after at least 2 hours from
14
15 exhaled NO measurements.
16
17

18 *1.4 Exhaled nitric oxide measurements*

19
20
21 NO measurements were performed using a chemo-luminescence analyser (model Hypair FeNO medisoft
22
23 Cardioline Exp'air, 2010) according to the ATS recommendations for online measurement of FeNO in adults
24
25 [20]. The analyser was sensitive to NO from 1 to 500 ppb with a resolution of 1 ppb. All measurements were
26
27 undertaken at ambient NO level of < 10 ppb. Exhaled NO was measured during slow exhalation from total
28
29 lung capacity against a positive pressure kept constantly between 5-20 cm H₂O. The exhalation flow rate
30
31 was kept constant through the use of a biofeedback visual display. FeNO was measured at flow-rates of 50,
32
33 100, 150 and 350 ml/s. For each flow rate, at least two technically adequate measurements were performed
34
35 and if a difference of more than 10% between these measurements was observed, a third assay was done.
36
37 The flow-independent NO parameters, CANO and maximum airway flux of NO (J'awNO), were calculated
38
39 using the linear model endorsed by ERS recent technical standard [21]: CANO and J'awNO, respectively,
40
41 correspond to Y-intercept and the slope of the linear relation between flow rate and FeNO•flow product. For
42
43 each patient a linear relationship was evaluated between the three points (100, 150 and 350 ml/s) of NO flux
44
45 against the flow.
46
47

48 *1.5 Data collection and reproducibility*

49
50
51 Each measurement was considered acceptable with a confidence rate > 95% and a flow stability > 90%. A
52
53 single investigator made FeNO measurements, guaranteeing inter- and intra-observer agreement.
54
55

56 *1.6 Statistical analysis*

1
2
3 Data are expressed as mean \pm standard deviation (SD). Comparisons between the IIP groups, CTD-ILD
4 group and controls were performed by Kruskal-Wallis test, with Dunn's multiple comparison test to
5 compare single groups. Correlations between CANO and PFT values parameters were made by Spearman's
6 test. We used non parametric tests because variables didn't show a normal distribution. ROC curves were
7 performed in order to evaluate the diagnostic accuracy of FeNO parameters for CTD-ILD. A p-value < 0.05
8 was considered statistically significant. Statistical analyses and figures were performed using Graph Pad
9 Prism 5.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

1.1 Population of the study

Demographic, functional, therapeutic, radiological features and eNO parameters were reported in Table 1. Populations of patients and controls were comparable: no significant differences were observed regarding age, smoking status and body mass index (BMI).

As expected, CTD-ILD patients were predominantly female, while the majority of IPF patients were male. The cohorts of healthy controls, NSIP and cHP patients were equally sex-matched. Chi-square test didn't reveal any statistical significant difference between the groups of patients and controls. Concerning PFTs, globally the cohort of patients reported a mild restrictive functional impairment associated to a moderate reduction of DLCO with no significant differences for any specific group, except for IPF patients that showed significantly lower values of TLC in respect to CTD-ILD patients.

1.2 eNO parameters and clinical-radiological features

All ILD patients presented significantly higher FeNO₁₅₀ and CANO levels than healthy controls ($p < 0.0001$ for both), while FeNO₃₅₀ values were significantly increased only in IPF, CTD-ILD and NSIP patients than controls ($p < 0.0001$). No statistical significant differences were found among FeNO₅₀, 100 and J'awNO levels of each subgroup. Concerning ILD population, CTD-ILD patients reported significantly higher values of FeNO₃₅₀ and CANO than the other subgroups (Fig.1).




Fig.1 Comparison of CANO levels in IPF, NSIP, cHP, CTD-ILD patients and healthy controls. CANO: alveolar concentration of nitric oxide; ppb: pars per billion. **: $p < 0.001$. (1.5 column fitting image)

No significant differences were reported among naive patients and patients in therapy with Pirfenidone, Nintedanib and immune-suppressants.

Concerning radiological data, there were no significant differences of eNO parameters among different CT patterns (typical UIP, probable UIP, indeterminate UIP and alternative to UIP) [22] in ILD population as well as in IPF and CTD-ILD subgroups.

1.3 Correlation with functional parameters

In the overall ILD population, we reported a significant inverse correlation between CANO and FVC ($r = -0.3864$, $p < 0.0001$) and DLCO ($r = -0.4129$, $p < 0.0001$). Regarding CTD-ILD, IPF and NSIP subgroups, CANO correlated inversely with FVC ($r = -0.3877$, $p = 0.0457$; $r = -0.4429$; $p = 0.0026$; $r = -0.7521$; $p = 0.0030$, respectively) and DLCO percentages ($r = -0.4589$, $p = 0.0025$; $r = -0.5171$; $p = 0.0005$; $r = -0.6521$; $p = 0.0030$, respectively); no other significant correlations were found.

1.4 Discriminating idiopathic IIPs and CTD-ILDs

ROC curves were performed in order to identify eNO parameters with adequate accuracy in detecting the presence of CTD. CTD-ILD patients showed higher FeNO 150 and 350 and CANO values than the other ILDs patients and were chosen for this purpose. CANO reported the best performance (area under the curve (AUC) = 0.795, $p < 0.0001$) in respect to FeNO 350 (AUC=0.751, $p = 0.0001$) and FeNO 150 (AUC=0.559, $p = 0.267$) (Fig. 2); a CANO cut-off value of 13.09 ppb showed a sensibility of 60% and a specificity of 80% in discriminating CTD-ILD from ILD.




Fig.2 ROC curve for CANO for the detection of CTD in the ILD population. AUC: area under the curve; CANO: alveolar concentration of nitric oxide. (1.5 column fitting image)

DISCUSSION

In this study, the features of eNO parameters in idiopathic (IPF, NSIP) and non-idiopathic ILDs (cHP and CTD-ILD) were analysed; in particular, our aim was to evaluate the potential utility of this non-invasive, reproducible biomarker in the diagnostic algorithm of lung diseases and to evaluate its potential as severity

1
2
3 marker of pulmonary interstitial diseases. Our study suggested the importance to perform multiple-flow
4 measurements of FeNO in patients with diffuse lung diseases as ILD patients reported higher values of
5 peripheral exhaled NO than controls, in line with previous findings [11]. Among eNO parameters, FeNO 350
6 and CANO, detected according to recent ERS statement, resulted the most promising biomarkers with the
7 highest statistical differences.
8
9
10
11
12

13
14 CTD-ILD patients showed the highest values of peripheral lung NO and CANO than other ILDs; this finding
15 could be explained by a more pronounced inflammatory process occurring in these rheumatic diseases
16 stimulating an aberrant overexpression of inducible NO synthetase in lung tissue, as reported [23]. Moreover,
17 DLCO percentages were not significantly different among ILD subgroups, suggesting that increased CANO
18 levels in CTD-ILD patients were not related to a worse diffusion lung capacity. Our results confirmed
19 previous findings by Tiev et al, who reported significantly increased CANO levels in SSC-ILD patients in
20 respect to IPF patients and healthy controls: our study enlarged these assumptions to other CTD-ILDs (like
21 RA-ILD and SS-ILD), contributing to the comprehension of NO pulmonary dynamics in these rare diseases.
22 Unfortunately, bronchoalveolar lavage (BAL) cellular analysis
23
24
25
26
27
28
29
30
31
32
33

34 Interestingly, CANO significantly correlated with FVC and DLCO, that are the most important prognostic
35 lung function parameters in ILDs. In previous studies, our group of research hypothesized that CANO could
36 be a surrogate marker of NO diffusion through alveolar capillary membrane: its progressive impairment due
37 to thickening of the membrane reduces washout of NO in alveolar spaces, inducing a NO retention
38 proportional to disease severity. The inflammatory burden in CTD-ILD may alter this relation between
39 CANO and alveolar diffusion of NO, impairing its potential role as severity biomarker. However, these
40 assumptions need to be further validated and the next step of our study will be to detect specific
41 physiological parameters, such as diffusion capacity of lung for NO (DLNO) in these populations of patients.
42
43
44
45
46
47
48
49
50

51 Concerning radiological data, no significant differences of eNO parameters were found among different CT
52 pattern of ILDs: to our knowledge, this is the first study investigating this task, regardless the publication of
53 the recent Fleischner society guidelines for IPF [24]. In 2007, Tiev reported a significant correlation between
54 CANO and quantitative radiological indexes of lung fibrosis, like ground-glass and reticular score: however,
55 the study included only patients with SSC-ILD and no specific CT patterns were reported [25]. According to
56
57
58
59
60

1
2
3 our results, eNO parameters fail to distinguish different CT patterns in a qualitative way, in agreement with
4
5 our previous study, where IPF and idiopathic NSIP didn't show significant differences [11].
6
7

8 Another relevant aim of our study was to determine the potential diagnostic role of NO parameters in the
9
10 diagnostic pathway of ILDs: both CANO and FeNO 350 showed a good accuracy in discriminating the
11
12 presence of CTD in patients with ILDs. International guidelines considered the exclusion of autoimmune
13
14 diseases as a primary requirement to perform a diagnosis of IPF: this task is not always simple as many ILD
15
16 patients have clinical or serological features of autoimmunity without reaching a definitive diagnosis of CTD
17
18 or reports lung fibrosis as first manifestation of CTD. Therefore, the need for new tools for detecting the
19
20 presence of CTD in ILDs is compelling. eNO measurement may contribute to this topic with numerous
21
22 advantages including the non-invasivity, the high reproducibility and very low cost.
23
24
25

26 In conclusion, a potential role of eNO measurement in the evaluation of ILD diagnosis and in the
27
28 management of ILD patients may be suggested. Among eNO parameters, FeNO 350 and CANO, detected
29
30 according to recent ERS statement, resulted the most promising biomarkers over-expressed in ILD patients
31
32 than controls. CTD-ILD patients showed the highest values of peripheral lung NO and CANO than other
33
34 ILDs, as a possible expression of more pronounced inflammatory processes occurring in these rheumatic
35
36 diseases.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	ILD population	CTD-ILD	IPF	NSIP	cHP	Controls	p-value
N°	134	46	50	19	19	60	
Male (%)	67 (50)	17 (37)	30 (60)	9 (47)	11 (58)	32 (53)	0.2112 Chi square: 5.843, df 4
Age (yrs)	63.5 ± 10.8	62.4 ± 11	65 ± 9.1	66 ± 10	59.2 ± 13	61 ± 5	0.2087 K=5.874
Smoking history (pack/year)	15 ± 23.8	12.5 ± 14.7	17.7 ± 24.9	19.2 ± 36.5	4.7 ± 7.8	5.2 ± 7.2	0.0987 K=9.271
Current smoker (%)	10 (7)	3 (6)	5 (10)	1 (5)	1 (5)	7 (11)	0.3956 Chi-square: 8.398, df 8
Former smoker (%)	64 (47)	21 (45)	29 (58)	8 (42)	6 (31)	18 (30)	0.3956 Chi-square: 8.398, df 8
Never smoker (%)	60 (45)	22 (48)	16 (32)	10 (52)	12 (63)	35 (58)	0.3956 Chi-square: 8.398, df 8
NO parameters							
FeNO 50 (ppb)	20.4 ± 8.4	19.8 ± 8.3	20.1 ± 8.1	19.9 ± 6.1	20.5 ± 10.8	15.8 ± 4.1	0.1400 K=6.923
FeNO 100 (ppb)	17.9 ± 7.4	18.8 ± 8	17 ± 6.9	16.8 ± 4.9	16.7 ± 6.5	13.1 ± 2.8	0.0954 K=9.054

FeNO 150 (ppb)	15.6 ± 6.9	16.3 ± 6.5	15.3 ± 7.1	15 ± 4.3	15 ± 4.2	10.8 ± 2.9	<0.0001† K=24.26
FeNO 350 (ppb)	10.7 ± 2.8	12.3 ± 2.7	10.2 ± 2	9.6±2.3	9.4 ± 3.8	7.2 ± 1.9	<0.0001‡ K=57.59
J'aw NO (nl/min)	38.7 ± 31.9	31.4 ± 30.8	40.1±32.6	41.3±29.2	49.4±37.5	35.3±22.3	0.1209 K=7.300
CANO (ppb)	12.3 ± 6.61	15.6 ± 7.2	10.9±5.4	10.1 ± 5.1	9 ± 5.1	4.5 ± 1.6	<0.0001¶ K=73.18
PFTs							n.a.
FVC % predicted value (l)	78.6 ± 23 (2.4 ± 0.9)	87.5 ± 21.4 (2.5 ± 0.7)	75.9 ± 22.2 (2.4 ± 0.9)	71 ± 23.4 (2.1 ± 0.8)	76.1 ± 23.3 (2.4 ± 1.1)		0.0831 K=6.671
FEV1 % predicted value (l)	77.9 ± 23 (1.8 ± 1.5)	85 ± 19 (1.9 ± 0.9)	77.1 ± 22.3 (1.9 ± 1.2)	73 ± 23.4 (1.8 ± 1.1)	70.2 ± 27.5 (1.8 ± 1.3)		0.0884 K=6.553
FEV1/FVC	80 ± 7.8	78.7 ± 6.2	79.7 ± 7.6	81.9 ± 9.4	81.8 ± 8.7		0.2881 K=3.764
TLC % predicted value (l)	81.9 ± 17.7 (4.5 ± 1.4)	90.6 ± 18.2 (4.7 ± 1.3)	77.6 ± 15.2 (4.4 ± 1.3)	75.5 ± 13.7 (4.3 ± 1.6)	85.3 ± 20.2 (4.9 ± 1.5)		0.0155* K=10.40
DLCO % predicted value	48.3 ± 18.7	53 ± 16.8	43.8 ± 17.2	45.3 ± 19.4	54.8 ± 21.5		0.0829 K=6.677
KCO % predicted value	72.5 ± 22.1	75.1 ± 22.7	68.1 ± 20.6	73 ± 21.2	80.6 ± 22		0.2647 K=3.970
HRCT scan pattern							
Typical UIP (%)	54 (40)	16 (35)	38 (76)	0	0		
Probable UIP (%)	17 (13)	7 (15)	8 (16)	0	2 (10)		

Indeterminate UIP (%)	23 (17)	14 (30)	4 (8)	0	5 (26)
Not UIP (%)	40 (30)	9 (19)	0	19 (100)	12 (63)
Therapy ongoing	70	36	18	10	6
Steroid (prednisone use mg/die)	51	25 (12.4 ± 9.3)	9 (11.1 ± 4)	11 (12.5 ± 5.9)	6 (14.5 ± 8.1)
Pirfenidone	6	0	6	0	0
Nintedanib	3	0	3	0	0
Methotrexate (mg/sett)	4	4 (12.5 ± 1.7)	0	0	0
Azathioprine (mg/die)	10	2 (100 ± 0)	5 (90 ± 20)	3 (100 ± 0)	0
Mycophenolate mophetile (g/die)	5	5 (1.7 ± 0.4)	0	0	0
Cyclophosphamide	2	1	0	1	0

Table 1. Demographic, functional, therapeutic data, radiological features and eNO parameters of the study population. †: difference in rank sum among IPF, NSIP, cHP, CTD-ILD and healthy controls: 38.2 (p<0.001); 47.43 (p<0.001); 44.9 (p<0.05); 51.28 (p<0.0001), respectively. ‡: difference in rank sum among IPF, NSIP, cHP, CTD-ILD and healthy controls: 50.74 (p<0.0001); 38.46 (not significant); 31.35 (not significant); 81.73 (p<0.0001), respectively; difference in rank sum among CTD-ILD patients and IPF, NSIP and cHP patients: 30.99 (p<0.05); 43.28 (p<0.001); 50.38 (p<0.0001), respectively. ¶: difference in rank sum among IPF, NSIP, cHP, CTD-ILD and healthy controls: 58.98 (p<0.0001); 52.72 (p<0.0001); 43.69 (p<0.05); 90.90 (p<0.0001), respectively; difference in rank sum among CTD-ILD patients and IPF, NSIP and cHP patients: 31.91 (p<0.001); 38.18 (p<0.001); 47.2 (p<0.001), respectively. *: difference in rank sum between IPF and CTD-ILD patients:-20.02; p<0.05. eNO: exhaled nitric oxide; FeNO: fractional exhaled nitric oxide; J'awNO: maximum airway flux of NO; CANO: alveolar concentration of nitric oxide; HRCT: high resolution computed tomography; K=Kruskal Wallis statistic. Df; degree of freedom.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Accepted Manuscript

REFERENCES

- [1] Wallace B., Vummidi D, Khanna D. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature *Curr Opin Rheumatol*. 2016 May;28(3):236-45
- [2] Gao H., Zhang X.W., He J., Zhang J., An Y., Sun Y., Jia R.L., Li S.G., Zhang L.J., Li Z.G. Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: A case-control study. *Medicine (Baltimore)*. 2018 Jun;97(24):e11003
- [3] Kim E.J., Elicker B.M., Maldonado F., Webb W.R., Ryu J.H., Van Uden J.H., Lee J.S., King T.E. Jr, Collard H.R. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J*. 2010 Jun;35(6):1322-8.
- [4] Steen V.D., Medsger T.A.. Changes in causes of death in systemic sclerosis, 1972-2002. *Ann Rheum Dis*. 2007 Jul;66(7):940-4.
- [5] Kennedy B., Branagan P., Moloney F., Haroon M., O'Connell O.J., O'Connor T.M., O'Regan K., Harney S., Henry M.T.. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2015; 32: 228–236.
- [6] Birch J., Barnes P.J., Passos J.F.. Mitochondria, telomeres and cell senescence: Implications for lung ageing and disease. *Pharmacol Ther* 2018; 183: 34–49.
- [7] Luckhardt T.R., Thannickal V.J.. Systemic sclerosis-associated fibrosis: an accelerated aging phenotype? *Curr Opin Rheumatol* 2015; 27: 571–576.
- [8] Moua T., Zamora Martinez A.C., Baqir M., Vassallo R., Limper A.H., Ryu J.H.. Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. *Respir Res* 2014; 15: 154.
- [9] Hua-Huy T., Le-Dong N.N., Duong-Quy S., Bei Y., Rivière S., Tiev K.P., Nicco C., Chéreau C., Batteux F., Dinh-Xuan A.T.. Increased exhaled nitric oxide precedes lung fibrosis in two murine models of systemic sclerosis. *J Breath Res*. 2015 Jun 16;9(3):036007.
- [10] Hua-Huy T., Tiev K.P., Chéreau C., Duong-Quy S., Cabane J., Dinh-Xuan A.T.. Increased alveolar concentration of nitric oxide is related to serum-induced lung fibroblast proliferation in patients with systemic sclerosis. *J Rheumatol*. 2010 Aug 1;37(8):1680-7.
- [11] Cameli P., Bargagli E., Refini R.M., Pieroni M.G., Bennett D., Rottoli P.. Exhaled nitric oxide in interstitial lung diseases. *Respir Physiol Neurobiol*. 2014 Jun 15;197:46-52

- [12] Tiev K.P., Coste J., Ziani M., Aubourg F., Cabane J., Dinh-Xuan A.T.. Diagnostic value of exhaled nitric oxide to detect interstitial lung disease in systemic sclerosis. *Sarcoidosis Vasc Diffuse Lung Dis.* 2009 Jul;26(1):32-8.
- [13] Tiev K.P., Hua-Huy T., Kettaneh A., Allanore Y., Le-Dong N.N., Duong-Quy S., Cabane J., Dinh-Xuan A.T.. Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma. *Thorax.* 2012 Feb;67(2):157-63.
- [14] Tiev K.P., Rivière S., Hua-Huy T., Cabane J., Dinh-Xuan A.T.. Exhaled NO predicts cyclophosphamide response in scleroderma-related lung disease. *Nitric Oxide.* 2014 Aug 31;40:17-21.
- [15] van den Hoogen F., Khanna D., Fransen J., Johnson S.R., Baron M., Tyndall A., Matucci-Cerinic M., Naden R.P., Medsger T.A. Jr, Carreira P.E., Riemekasten G., Clements P.J., Denton C.P., Distler O., Allanore Y., Furst D.E., Gabrielli A., Mayes M.D., van Laar J.M., Seibold J.R., Czirjak L., Steen V.D., Inanc M., Kowal-Bielecka O., Müller-Ladner U., Valentini G., Veale D.J., Vonk M.C., Walker U.A., Chung L., Collier D.H., Ellen Csuka M., Fessler B.J., Guiducci S., Herrick A., Hsu V.M., Jimenez S., Kahaleh B., Merkel P.A., Sierakowski S., Silver R.M., Simms R.W., Varga J., Pope J.E.. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. *Send to Ann Rheum Dis.* 2013 Nov;72(11):1747-55.
- [16] Shiboski C.H., Shiboski S.C., Seror R., Criswell L.A., Labetoulle M., Lietman T.M., Rasmussen A., Scofield H., Vitali C., Bowman S.J., Mariette X.; International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/ European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. *Ann Rheum Dis* 2017;76:9–16.
- [17] Smolen J.S., Landewé R., Bijlsma J., Burmester G., Chatzidionysiou K., Dougados M., Nam J., Ramiro S., Voshaar M., van Vollenhoven R., Aletaha D., Aringer M., Boers M., Buckley C.D., Buttgereit F., Bykerk V., Cardiel M., Combe B., Cutolo M., van Eijk-Hustings Y., Emery P., Finckh A., Gabay C., Gomez-Reino J., Gossec L., Gottenberg J.E., Hazes J.M.W., Huizinga T., Jani M., Karateev D., Kouloumas M., Kvien T., Li Z., Mariette X., McInnes I., Mysler E., Nash P., Pavelka K., Poór G., Richez C., van Riel P., Rubbert-Roth A., Saag K., da Silva J., Stamm T., Takeuchi T., Westhovens R., de Wit M., van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Send to Ann Rheum Dis.* 2017 Jun;76(6):960-977.

- 1
2
3
4 [18] Miller M.R., Crapo R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., Enright
5 P., van der Grinten C.P., Gustafsson P., Jensen R., Johnson D.C., MacIntyre N., McKay R.,
6 Navajas, D., Pedersen O.F., Pellegrino R., Viegi G., Wanger J.; ATS/ERS Task Force. 2005.
7 General considerations for lung function testing. *Eur Respir J.* 26(1):153-61.
8
9 [19] Graham B.L., Brusasco V., Burgos F., Cooper B.G., Jensen R., Kendrick A., MacIntyre N.R.,
10 Thompson B.R., Wanger J. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in
11 the lung. *Eur Respir J.* 2017 Jan 3;49(1). pii: 1600016.
12
13 [20] American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for
14 standardized procedures for the online and offline measurement of exhaled lower respiratory nitric
15 oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med.* 2005 Apr 15;171(8):912-30.
16
17 [21] Horváth I., Barnes P.J., Loukides S., Sterk P.J., Högman M., Olin A.C., Amann A., Antus B.,
18 Baraldi E., Bikov A., Boots A.W., Bos L.D., Brinkman P., Bucca C., Carpagnano G.E., Corradi M.,
19 Cristescu S., de Jongste J.C., Dinh-Xuan A.T., Dompeling E., Fens N., Fowler S., Hohlfeld J.M.,
20 Holz O., Jöbsis Q., Van De Kant K., Knobel H.H., Kostikas K., Lehtimäki L., Lundberg J,
21 Montuschi P., Van Muylem A., Pennazza G., Reinhold P., Ricciardolo F.L.M., Rosias P.,
22 Santonico M., van der Schee M.P., van Schooten F.J., Spanevello A., Tonia T., Vink T.J.. A
23 European Respiratory Society technical standard: exhaled biomarkers in lung disease. *Eur Respir J.*
24 2017 Apr 26;49(4).
25
26 [22] Raghu G., Remy-Jardin M., Myers J.L., Richeldi L., Ryerson C.J., Lederer D.J., Behr J., Cottin
27 V., Danoff S.K., Morell F., Flaherty K.R., Wells A., Martinez F.J., Azuma A., Bice T.J., Bouros D.,
28 Brown K.K., Collard H.R., Duggal A., Galvin L., Inoue Y., Jenkins R.G., Johkoh T., Kazerooni
29 E.A., Kitaichi M., Knight S.L., Mansour G., Nicholson A.G., Pipavath S.N.J., Buendía-Roldán I.,
30 Selman M., Travis W.D., Walsh S., Wilson K.C.; American Thoracic Society, European
31 Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.
32 Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice
33 Guideline. *Am J Respir Crit Care Med.* 2018 Sep 1;198(5):e44-e68.
34
35 [23] Parra ER, Aguiar Junior AC, Silva LO, Souza HS, Espinoza JD, Capelozzi VL. Morphometric
36 evaluation of nitric oxide synthase isoforms and their cytokine regulators predict pulmonary
37 dysfunction and survival in systemic sclerosis. *Braz J Med Biol Res.* 2013 Oct;46(10):881-91.
38
39 [24] Lynch D.A., Sverzellati N., Travis W.D., Brown K.K., Colby T.V., Galvin J.R., Goldin J.G.,
40 Hansell D.M., Inoue Y., Johkoh T., Nicholson A.G., Knight S.L., Raoof S., Richeldi L., Ryerson
41 C.J., Ryu J.H., Wells A.U.. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner
42 Society White Paper. *Lancet Respir Med.* 2018 Feb;6(2):138-153.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 [25] Tiev K.P., Cabane J., Aubourg F., Kettaneh A., Ziani M., Mouthon L., Duong-Quy S., Fajac I.,
5
6 Guillevin L., Dinh-Xuan A.T.. Severity of scleroderma lung disease is related to alveolar
7
8 concentration of nitric oxide. *Eur Respir J.* 2007 Jul;30(1):26-30.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Accepted Manuscript